Literature DB >> 7574490

Generation, translocation, and presentation of MHC class I-restricted peptides.

M T Heemels1, H Ploegh.   

Abstract

The T lymphocytes of the vertebrate immune system look for changes that take place within the organism by examining a display of peptides at the cell surface. These peptides are presented by the products of the major histocompatibility complex (MHC). MHC class I products present peptides derived by proteolysis of cytosolic proteins by the multicatalytic protease, the proteasome. These peptides are translocated from the cytosol into the endoplasmic reticulum by a dedicated peptide transporter, the transporter associated with antigen presentation (TAP). TAP consists of two subunits, and translocates peptides that are approximately 8-12 residues in length. The COOH terminal residue of the peptide is a major determinant in the specificity of translocation. Following translocation, peptides bind to MHC class I molecules, which depend on the peptide ligand as well as on interactions with chaperonins for proper folding. These complexes then egress from the ER and are transported to their final destination, the cell surface.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7574490     DOI: 10.1146/annurev.bi.64.070195.002335

Source DB:  PubMed          Journal:  Annu Rev Biochem        ISSN: 0066-4154            Impact factor:   23.643


  105 in total

Review 1.  The proteasome: a macromolecular assembly designed for controlled proteolysis.

Authors:  P Zwickl; D Voges; W Baumeister
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  Protective cytotoxic T lymphocyte responses induced by DNA immunization against immunodominant and subdominant epitopes of Listeria monocytogenes are noncompetitive.

Authors:  T Yamada; H Uchiyama; T Nagata; M Uchijima; T Suda; K Chida; H Nakamura; Y Koide
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity.

Authors:  A M Doling; J D Ballard; H Shen; K M Krishna; R Ahmed; R J Collier; M N Starnbach
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

4.  Modeling the interactions of a peptide-major histocompatibility class I ligand with its receptors. I. Recognition by two alpha beta T cell receptors.

Authors:  D Rognan; A Stryhn; L Fugger; S Lyngbaek; J Engberg; P S Andersen; S Buus
Journal:  J Comput Aided Mol Des       Date:  2000-01       Impact factor: 3.686

5.  Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome.

Authors:  M Raghavan
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

6.  A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation.

Authors:  U Reusch; W Muranyi; P Lucin; H G Burgert; H Hengel; U H Koszinowski
Journal:  EMBO J       Date:  1999-02-15       Impact factor: 11.598

7.  Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus.

Authors:  H Hengel; U Reusch; G Geginat; R Holtappels; T Ruppert; E Hellebrand; U H Koszinowski
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.

Authors:  J T Voeten; G F Rimmelzwaan; N J Nieuwkoop; R A Fouchier; A D Osterhaus
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

9.  Intracellular trafficking pathway of newly synthesized CD1b molecules.

Authors:  V Briken; R M Jackman; S Dasgupta; S Hoening; S A Porcelli
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

10.  The export of major histocompatibility complex class I molecules from the endoplasmic reticulum of rat brown adipose cells is acutely stimulated by insulin.

Authors:  D Malide; J W Yewdell; J R Bennink; S W Cushman
Journal:  Mol Biol Cell       Date:  2001-01       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.